Cemex S.A.B. De C.V. (CX): Today's Featured Industrial Goods Laggard

Cemex S.A.B. de C.V ( CX) pushed the Industrial Goods sector lower today making it today's featured Industrial Goods laggard. The sector as a whole closed the day down 0.2%. By the end of trading, Cemex S.A.B. de C.V fell 10 cents (-1.3%) to $7.41 on light volume. Throughout the day, 7.8 million shares of Cemex S.A.B. de C.V exchanged hands as compared to its average daily volume of 11.4 million shares. The stock ranged in price between $7.36-$7.53 after having opened the day at $7.52 as compared to the previous trading day's close of $7.51. Other companies within the Industrial Goods sector that declined today were: THT Heat Transfer Technology ( THTI), down 17.1%, Highpower International ( HPJ), down 10.8%, Guanwei Recycling ( GPRC), down 9.9%, and Arotech Corporation ( ARTX), down 6.7%.

CEMEX, S.A.B. de C.V., through its subsidiaries, engages in the production, marketing, distribution, and sale of cement, ready-mix concrete, aggregates, and other construction materials worldwide. Cemex S.A.B. de C.V has a market cap of $7.88 billion and is part of the materials & construction industry. Shares are up 34.3% year to date as of the close of trading on Friday. Currently there are five analysts that rate Cemex S.A.B. de C.V a buy, one analyst rates it a sell, and seven rate it a hold.

TheStreet Ratings rates Cemex S.A.B. de C.V as a sell. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the industrial goods sector could consider Industrial Select Sector SPDR ( XLI) while those bearish on the industrial goods sector could consider ProShares Short Dow 30 ( DOG).

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing